Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Neurology|March 29, 2013
Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MSJeremy Hobart, Andrew R Blight, Andrew Goodman, et al.Spine Deformity|December 28, 2018
Expansion Thoracoplasty as a Life-Saving Procedure in an Adolescent With Severe Spinal Deformity and Sacral AgenesisChelsea S Mathews, David B Bumpass, Frances Lynn McCullough, et al.Pharmaceutical Statistics|September 12, 2007
Conditional approval: discussion points from the PSI conditional approval expert groupKevin Carroll, Hilary Chaudri Ross, Dan Evans, et al.BMC Medical Research Methodology|July 14, 2016
Best practice for analysis of shared clinical trial dataSally Hollis, Christine Fletcher, Frances Lynn, et al.Journal of Neurology|October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSBianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.Journal of Neurology|March 25, 2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELMichael Hutchinson, Ludwig Kappos, Peter A Calabresi, et al.Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.Pageof 2